CD8A and neoplasm: In the case of acute inflammation following tumor antigen uptake or activation by a Toll-like receptor (TLR) agonist, mature DCs may regulate the anti-tumor immune response by modulating the inflammatory response through various mechanisms (e.g., cross-presentation of tumor antigens and priming of tumor-specific CD8+ T cells, polarization of immune cells towards the anti-tumor phenotype, recruitment of NK cells, thereby maintaining the T cell response) [111,112].